- Report
- December 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- May 2024
- 139 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 202 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Clinical Trials
- November 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- December 2024
- 84 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Clinical Trials
- August 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2025
- 200 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- November 2018
- 147 Pages
Global
From €1307EUR$1,375USD£1,098GBP
€2614EUR$2,750USD£2,196GBP
- Report
- July 2023
- 135 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- July 2023
- 67 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- November 2023
- 140 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- February 2024
- 168 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2023
- 168 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- February 2024
- 112 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2022
- 121 Pages
Global
From €4516EUR$4,750USD£3,794GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more